510(k) Summary as Required by 21 CFR 807.92

A. 510(k) Number K121576   
B. Purpose for New device   
Submission   
C. Measurand Anti-cyclic citrullinated peptide (CCP) antibodies   
D. Type of test Semi-quantitative chemiluminescent immunometric assay   
E. Applicant: Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, NY 10591   
F. Proprietary and IMMULITE $^ { \mathrm { \infty } } 2 0 0 0$ Anti-CCP IgG Assay   
Established   
Names:   
G. Regulatory   
Information:   
1. Regulation 21 CFR 866.5775   
section:

2. Classification: Class II

3. Products Codes: NHX - Antibodies, Anti-Cyclic Citrullinated Peptide (CCP) JIT- Calibrators JJX - Single Analyte Control

4. Panel:

Immunology (82)

# H. Intended Use:

The IMMULITE 2000 Anti-CCP IgG assay is an in vitro diagnostic immunoassay for the semi-quantitative determination of the IgG class of autoantibodies specific to cyclic citrullinated peptide (CCP) in human serum (including Serum Separator Tubes) or plasma (EDTA or lithium heparin) on the IMMULITE® 2000 system. Detection of antiCCP antibodies is used as an aid in the diagnosis of Rheumatoid Arthritis (RA) and should be used in conjunction with other clinical information. Autoantibody levels represent one parameter in a multicriteria diagnostic process, encompassing both clinical and laboratorybased assessments.

Traditional 510(k) Premarket Notification IMMULITE® 2000 Anti-CCP IgG Assay 510(k) Summary of Safety and Effectiveness

# I. Device Description:

The IMMULITE 2000 Anti-CCP IgG assay consists of the following components:

Anti-CCP IgG bead pack coated with cyclic citrullinated peptide   
(CCP) antigen   
Anti-CCP IgG reagent wedge containing bovine calf intestine   
conjugated to a monoclonal murine anti-human IgG antibody   
Anti-CCP IgG adjustors, low and high, containing lyophilized   
human serum with IgG reactive to CCP   
Anti-CCP IgG controls, negative and positive, containing human   
serum   
Autoantibody sample diluent containing protein/buffer matrix

J. Substantial Equivalence Information:

Predicate device name: DIASTATTM Anti-Cyclic Citrullinated Peptide (anti-CCP) ELISA

510(k) number: k023285

# Comparison with predicate:

A comparison of the device features, intended use, laboratory data and other information demonstrates that the IMMULITE ® 2000 Anti-CCP IgG assay is substantially equivalent to the predicate device, DIASTATTM Anti-Cyclic Citrullinated Peptide (anti-CCP) ELISA, as summarized in the following tables.

Traditional 510(k) Premarket Notification IMMULITE® 2000 Anti-CCP IgG Assay 510(k) Summary of Safety and Effectiveness   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>SIMILARITIES</td></tr><tr><td></td><td rowspan=1 colspan=2>Item</td><td rowspan=1 colspan=2>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>IMMULITE 2000 Anti-CCP IgGAssay</td><td rowspan=1 colspan=1>DIASTATTM Anti-CyclicCitrullinated Peptide (anti-CCP)ELISA</td></tr><tr><td></td><td rowspan=1 colspan=2>Intended Use</td><td rowspan=1 colspan=2>The IMMULITE® 2000 Anti-CCPIgG assay is an in vitro diagnosticimmunoassay for the semi-quantitative determination of theIgG class of autoantibodiesspecific to cyclic citrullinatedpeptide (CCP) in human serum orplasma on the IMMULITE®2000system. Detection of anti-CCPantibodies is used as an aid in thediagnosis of Rheumatoid Arthritis(RA) and should be used inconjunction with other clinicalinformation. Autoantibody levelsrepresent one parameter in a multi-criteria diagnostic process,encompassing both clinical andlaboratory-based assessments.</td><td rowspan=1 colspan=1>The DIASTATTM Anti-CCP test is asemi-quantitative/qualitativeenzyme-linked immunosorbent assay(ELISA) for the detection of the IgGclass of autoantibodies specific tocyclic citrullinated peptide (CCP) inhuman serum or plasma. The test isintended to aid in the diagnosis ofRheumatoid Arthritis (RA) and is notdefinitive in isolation.Autoantibody levels represent oneparameter in a multi-criteriondiagnostic process, encompassingboth clinical and laboratory-basedassessments.</td></tr><tr><td rowspan=1 colspan=2>Antigen Usedon the SolidPhase</td><td rowspan=1 colspan=2>Synthetic cyclic citrullinatedpeptide, second generation</td><td rowspan=1 colspan=2>Same</td></tr><tr><td rowspan=1 colspan=2>DetectingAntibody</td><td rowspan=1 colspan=2>Murine monoclonal antibodyconjugated to AlkalinePhosphatase</td><td rowspan=1 colspan=2>Same</td></tr><tr><td rowspan=1 colspan=2>Controls</td><td rowspan=1 colspan=2>Negative and positive kit controls</td><td rowspan=1 colspan=2>Same</td></tr><tr><td rowspan=1 colspan=2>Interference</td><td rowspan=1 colspan=2>Rheumatoid factor (up to 200IU/mL does not interfere with anti-CCP antibody results.</td><td rowspan=1 colspan=2>Same</td></tr></table>

Traditional 510(k) Premarket Notification IMMULITE® 2000 Anti-CCP IgG Assay 510(k) Summary of Safety and Effectiveness   

<table><tr><td rowspan=1 colspan=3>DIFFERENCES</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>IMMULITE® 2000 Anti-CCPIgG Assay</td><td rowspan=1 colspan=1>DIASTATTM Anti-CyclicCitrullinated Peptide (anti-CCP)ELISA</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Solid-phase, two-cycle sequentialchemiluminescent immunometricassay</td><td rowspan=1 colspan=1>Enzyme-linked immunosorbentassay (ELISA)</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>Chemiluminescent</td><td rowspan=1 colspan=1>Mg2+, phenolphthaleinmonophosphate (PMP)</td></tr><tr><td rowspan=1 colspan=1>Sample size</td><td rowspan=1 colspan=1>5 μL(20 μL of the prediluted sample)</td><td rowspan=1 colspan=1>10μL(100 μL of the prediluted sample)</td></tr><tr><td rowspan=1 colspan=1>SampleDilution</td><td rowspan=1 colspan=1>1:40</td><td rowspan=1 colspan=1>.1:100</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, lithiumheparin)</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, lithiumheparin, sodium citrate)</td></tr><tr><td rowspan=1 colspan=1>Incubation</td><td rowspan=1 colspan=1>30 minutes, 30 minutes, 5 minutes</td><td rowspan=1 colspan=1>60 minutes, 30 minutes, 30 minutes</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>1.50 U/mL</td><td rowspan=1 colspan=1>0.05 U/mL</td></tr><tr><td rowspan=1 colspan=1>ExpectedValues(apparentlyhealthydonors)</td><td rowspan=1 colspan=1>Median: &lt;1.50 U/mLRange: &lt;1.50 U/mL</td><td rowspan=1 colspan=1>Mean : 0.63 ± 0.419U/mLRange: 0.05 - 3.8U/mL</td></tr><tr><td rowspan=1 colspan=1>ReportableRange</td><td rowspan=1 colspan=1>1.50 - 200 U/mL</td><td rowspan=1 colspan=1>0.05 - 100U/mL</td></tr><tr><td rowspan=1 colspan=1>Assay Cut-off</td><td rowspan=1 colspan=1>≥4.00 U/mL = Reactive</td><td rowspan=1 colspan=1>&gt;5 U/mL = Positive</td></tr><tr><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=1>Bilirubin (up to 0.2 mg/L),hemoglobin (up to 500 mg/dL),and triglycerides (up to 1.5 g/dL)do not interfere with anti-CCPantibody results.Total protein not assessed.</td><td rowspan=1 colspan=1>Bilirubin (up to 0.2 mg/mL),hemoglobin (up to 400 mg/dL), andintralipid (up to 15 mg/mL) do notinterfere with anti-CCP antibodyresults.Total Protein up to 120 mg/mL doesnot interfere with anti-CCP antibodyresults.</td></tr></table>

# K. Standard/Guidance Documents Referenced:

CLSI EP5-A2 Evaluation of Precision Performance of Quantitative Measurement Methods CLSI EP6-A Evaluation of the Linearity of Quantitative Measurement CLSI EP17-A Protocols for Determination of Limits of Detection and Limits of Quantitation CEN 13640 Stability Testing of In Vitro Diagnostic Reagents

# L. Test Principle:

The IMMULITE® 2000 Anti-CCP IgG assay is a solid phase, two-cycle sequential chemiluminescent immunometric assay. In the first cycle, the patient sample and the buffer are incubated together with the coated bead for 30 minutes. During this time, human IgG in the sample binds to CCP on the bead. Unbound sample is then removed by centrifugal washes. In the second cycle, the enzyme conjugated monoclonal murine antihuman IgG is added to the original reaction tube for additional 30 minutes incubation. The enzyme conjugated monoclonal murine anti-human IgG antibody binds to immobilized anti-CCP IgG on the bead. The unbound enzyme conjugate is removed by centrifugal washes. Finally, chemiluminescent substrate is added to the reaction tube containing the bead and the signal is generated in proportion to the bound enzyme.

# M. Performance Characteristics

# 1. Analytical Performance:

a. Precision/Reproducibility:

Precision was evaluated using a protocol based on CLSI document EP05-A2, Evaluation of Precision Performance of Quantitative Measurement Methods. Eleven samples were tested over a period of 20 days, using 2 IMMULITE® 2000 instruments with 2 reagent lots each, 2 runs per day and 2 replicates per sample. The work list consisted of a high control and 2 sets of six-member precision panels: one serum donor panel and one lithium heparin plasma donor panel. Precision panels were prepared by pooling the samples and spiking to the desired concentration with a stock Anti-CCP reactive sample. The sample concentrations are detailed in the table below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Target Concentration (U/mL)</td></tr><tr><td rowspan=1 colspan=1>LPIC2.101 Positive control</td><td rowspan=1 colspan=1>46.0</td></tr><tr><td rowspan=1 colspan=1>SERP2 serum donor panel</td><td rowspan=1 colspan=1>2.96</td></tr><tr><td rowspan=1 colspan=1>SERP3 sserum donor panel</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>SERP4serum donor panel</td><td rowspan=1 colspan=1>9.0</td></tr><tr><td rowspan=1 colspan=1>SERP5serum donor panel</td><td rowspan=1 colspan=1>37.4</td></tr><tr><td rowspan=1 colspan=1>SERP6 sserum donor panel</td><td rowspan=1 colspan=1>135.5</td></tr><tr><td rowspan=1 colspan=1>PLASP2 Li Heparin donor panel</td><td rowspan=1 colspan=1>2.59</td></tr><tr><td rowspan=1 colspan=1>PLASP33 Li Heparin donor panel</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>PLASP4Li Heparin donor panel</td><td rowspan=1 colspan=1>9.0</td></tr><tr><td rowspan=1 colspan=1>PLASP5 Li Heparin donor panel</td><td rowspan=1 colspan=1>37.4</td></tr></table>

Traditional 510(k) Premarket Notification IMMULITE $\textcircled { 1 9 } \textcircled { 2 0 0 0 }$ Anti-CCP IgG Assay 510(k) Summary of Safety and Effectiveness   

<table><tr><td>Sample</td><td>Target Concentration (U/mL)</td></tr><tr><td>PLASP6 Li Heparin donor panel</td><td>135.5</td></tr></table>

Precision data is summarized in the table below:

<table><tr><td rowspan=1 colspan=2>20-DayImprecisionN=320</td><td rowspan=1 colspan=2>Between Lot</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>MeanU/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LPIC2</td><td rowspan=1 colspan=1>47.4</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.05</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>SERP2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>13.6</td></tr><tr><td rowspan=1 colspan=1>SERP3</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>SERP4</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>SERPS</td><td rowspan=1 colspan=1>37.6</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.54</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>SERP6</td><td rowspan=1 colspan=1>144.0</td><td rowspan=1 colspan=1>2.29</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.17</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.45</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>6.98</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>PLASP2</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>12.8</td></tr><tr><td rowspan=1 colspan=1>PLASP3</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>8.6</td></tr><tr><td rowspan=1 colspan=1>PLASP4</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>PLASP5</td><td rowspan=1 colspan=1>38.5</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.57</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.96</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>PLASP6</td><td rowspan=1 colspan=1>141.5</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.23</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.87</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>5.52</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>7.11</td><td rowspan=1 colspan=1>5.0</td></tr></table>

Reproducibility was evaluated using two different reagent lots at three external testing sites, using serum donor panels from the precision study. The protocol was run over 10 days, 2 runs per day, with 4 replicates per run for the sample pools and control material.

The results for reproducibility, pooled across 3 sites, are presented in the table below.   

<table><tr><td rowspan=2 colspan=1>SampleID</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=2>WithinRun</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenSite</td><td rowspan=1 colspan=2>TotalWithin-Device</td><td rowspan=1 colspan=2>TotalWithin-Lot</td></tr><tr><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex (%)</td><td rowspan=1 colspan=1>Cv</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=15>(%)Reagent Lot 201</td></tr><tr><td rowspan=1 colspan=1>SERP2</td><td rowspan=1 colspan=1>244</td><td rowspan=1 colspan=1>1.94</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>10.1</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>14.8</td></tr><tr><td rowspan=1 colspan=1>SERP3</td><td rowspan=1 colspan=1>244</td><td rowspan=1 colspan=1>3.98</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>SERP4</td><td rowspan=1 colspan=1>244</td><td rowspan=1 colspan=1>8.08</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>SERPS</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>36.07</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>SERP</td><td rowspan=1 colspan=1>244</td><td rowspan=1 colspan=1>139.18</td><td rowspan=1 colspan=1>5.11</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>2.84</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>3.79</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>5.98</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>7.08</td><td rowspan=1 colspan=1>5.1</td></tr></table>

Traditional 510(k) Premarket Notification IMMULITE® 2000 Anti-CCP IgG Assay 510(k) Summary of Safety and Effectiveness   

<table><tr><td rowspan=2 colspan=1>SampleID</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=2>WithinRun</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenSite</td><td rowspan=1 colspan=2>TotalWithin-Device</td><td rowspan=1 colspan=2>TotalWithin-Lot</td></tr><tr><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDIndex</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>LPIC2</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>45.66</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>2.21</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=15>Reagent Lot 202SERP2228 1.61</td></tr><tr><td rowspan=1 colspan=1>SERP2</td><td rowspan=1 colspan=1>228</td><td rowspan=1 colspan=1>1.61</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.13.</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>14.4</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>17.6</td></tr><tr><td rowspan=1 colspan=1>SERP3</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.72</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>SERP4</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>8.02</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>SERP5</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>36.79</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>2.14</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>SERP6</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>139.61</td><td rowspan=1 colspan=1>6.27</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>2.46</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.81</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.81</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>8.28</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>9.58</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>LPIC2</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>43.54</td><td rowspan=1 colspan=1>2.49</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.61</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.97</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>3.39</td><td rowspan=1 colspan=1>7.8</td></tr></table>

b. Linearity/assay Reportable Range: The Anti-CCP Linearity study was performed according to the CLSI document EP6-A; Evaluation of the Linearity of Quantitative Measurement Methods. A dilution series was prepared by combining a reactive serum pool and a non-reactive serum pool in different ratios to produce 1 1 dilutions covering the assay measuring range (1.50 U/mL to 200 U/mL). The dilutions were run in triplicate on one IMMULITE®2000 instrument. Results are shown below. Since this assay has no reference material or method and is traceable to internal standard, the recovery is defined as the difference between the observed dose and the fitted values of the linear equation.

Dose Recovery:   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>ExpectedDose(U/mL)</td><td rowspan=1 colspan=1>MeanObservedDose(U/mL)</td><td rowspan=1 colspan=1>LinearFittedDose(U/mL)</td><td rowspan=1 colspan=1>Mean% Recovery</td></tr><tr><td rowspan=1 colspan=1>P3</td><td rowspan=1 colspan=1>181.51</td><td rowspan=1 colspan=1>182.93</td><td rowspan=1 colspan=1>183.00</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>P4</td><td rowspan=1 colspan=1>151.38</td><td rowspan=1 colspan=1>158.52</td><td rowspan=1 colspan=1>152.70</td><td rowspan=1 colspan=1>103.8%</td></tr><tr><td rowspan=1 colspan=1>P5</td><td rowspan=1 colspan=1>121.26</td><td rowspan=1 colspan=1>127.68</td><td rowspan=1 colspan=1>122.40</td><td rowspan=1 colspan=1>104.3%</td></tr><tr><td rowspan=1 colspan=1>P6</td><td rowspan=1 colspan=1>91.13</td><td rowspan=1 colspan=1>93.00</td><td rowspan=1 colspan=1>92.09</td><td rowspan=1 colspan=1>101.0%</td></tr><tr><td rowspan=1 colspan=1>P7</td><td rowspan=1 colspan=1>61.00</td><td rowspan=1 colspan=1>61.91</td><td rowspan=1 colspan=1>61.79</td><td rowspan=1 colspan=1>100.2%</td></tr><tr><td rowspan=1 colspan=1>P8</td><td rowspan=1 colspan=1>30.87</td><td rowspan=1 colspan=1>28.32</td><td rowspan=1 colspan=1>31.49</td><td rowspan=1 colspan=1>89.9%</td></tr><tr><td rowspan=1 colspan=1>P9</td><td rowspan=1 colspan=1>15.80</td><td rowspan=1 colspan=1>17.01</td><td rowspan=1 colspan=1>16.34</td><td rowspan=1 colspan=1>104.1%</td></tr><tr><td rowspan=1 colspan=1>P10</td><td rowspan=1 colspan=1>12.07</td><td rowspan=1 colspan=1>11.89</td><td rowspan=1 colspan=1>12.58</td><td rowspan=1 colspan=1>94.5%</td></tr><tr><td rowspan=1 colspan=1>P11</td><td rowspan=1 colspan=1>8.33</td><td rowspan=1 colspan=1>8.58</td><td rowspan=1 colspan=1>8.82</td><td rowspan=1 colspan=1>97.3%</td></tr><tr><td rowspan=1 colspan=1>P12</td><td rowspan=1 colspan=1>4.43</td><td rowspan=1 colspan=1>4.48</td><td rowspan=1 colspan=1>4.89</td><td rowspan=1 colspan=1>91.5%</td></tr><tr><td rowspan=1 colspan=1>P13</td><td rowspan=1 colspan=1>2.64</td><td rowspan=1 colspan=1>2.40</td><td rowspan=1 colspan=1>3.10</td><td rowspan=1 colspan=1>77.4%</td></tr></table>

c.Traceability, Stability, Expected Values (controls, calibrators, methods):

Traditional 510(k) Premarket Notification IMMULITE® 2000 Anti-CCP IgG Assay 510(k) Summary of Safety and' Effectiveness

Traceability - There is no recognized standard reference material for Anti-CCP. The IMMULITE® 2000 Anti-CCP IgG assay is traceable to an internal standard and manufactured using qualified materials and measurement procedures.

Stability - Freshly opened and prepared IMMULITE® 2000 Anti-CCP IgG adjustors and controls showed 30 days open vial stability when stored at 2-8°C, or 6 months (aliquotted) when stored at -20°C. The IMMULITE® 2000 Anti-CCP IgG reagent wedge is stable at $2 { - } 8 ^ { \circ } \mathrm { C }$ until the expiration date on the label.

Adjustors and Controls are prepared in house and arbitrary units are assigned during the development process. Calibrator and Control values are summarized in the tables below. The listed values are approximate values, as the values are lot specific.

<table><tr><td rowspan=1 colspan=1>Adjustor</td><td rowspan=1 colspan=1>Dose Range U/mL</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>2.0 - 5.0</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>40 - 60</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>Target* U/mL</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>&lt;1.5</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>44</td></tr></table>

# d. Detection Limit:

Limit of Blank (LoB): An Anti-CCP nonreactive donor sample was used as a blank and was analyzed on three IMMULITE® 2000 instruments over 5 days. The sample was tested twice daily using two lots of reagent with two replicate per run. The LoB result was determined by applying a nonparametric principle based on ranked ordered value using the following equation:

LoB = [NB(p/100)+0.5]; where p=(100-α) = 95 and NB = number of blank measurements $= 7 3 2$ EY

The LoB was the average of the ranked results at positions 695 and 696. The LoB was determined to be $0 . 2 6 ~ \mathrm { U / m L }$ .

Limit of Detection (LoD): Five Anti-CCP serum samples (mean concentrations ranging from 0.26 to 2.5 U/mL) were assayed in replicates of 6 using 2 reagent kit lots run for 5 days with 2 runs per day. Two instrument and 2 operators generated 960 observations.

# Traditional 510(k) Premarket Notification IMMULITE® 2000 Anti-CCP IgG Assay 510(k) Summary of Safety and Effectiveness

LoD = LoB +median $- 5 ^ { \mathrm { t h } }$ percentile.

# e. Analytical Specificity:

Endogenous Interferents: A study was conducted to assess the effect of several endogenous interferents on the IMMULITE®2000 Anti-CCP IgG assay. Testing consisted of the addition of human serum albumin, triglycerides, hemoglobin, bilirubin (conjugated and unconjugated), and rheumatoid factor into the samples. One control sample and five (5) different sample pools with differing Anti-CCP concentrations (range 2.0 U/mL to 205 U/mL) were used. Each potentially interfering substance was spiked separately into the sample pools. Results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>IMMULITE 2000 Anti-CCP:Summary of EndogenousInterferents in Anti-CCPSamples</td><td rowspan=1 colspan=1>%Difference:Control Dose/ Test Dose:Lot 201</td><td rowspan=1 colspan=1>%Difference:Control Dose/ Test Dose:Lot 202</td><td rowspan=1 colspan=1>Mean %InterferenceLot 201 &amp; Lot202</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin (12g/dL)</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Triglycerides (1.5 g/dL)</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>-1.4</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin (500 mg/dL)</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>Conjugated Bilirubin (0.2mg/mL)</td><td rowspan=1 colspan=1>-1.6</td><td rowspan=1 colspan=1>-2.0</td><td rowspan=1 colspan=1>-1.8</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin (0.2mg/mL)</td><td rowspan=1 colspan=1>-3.6</td><td rowspan=1 colspan=1>-2.9</td><td rowspan=1 colspan=1>-3.3</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (200IU/mL)</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>-4.1</td><td rowspan=1 colspan=1>-1.7</td></tr></table>

Less than 10% mean interference was found with all endogenous interfering substance as follows: Human Serum Albumin (up to 12g/dL); Triglycerides (up to 1.5 g/dl); Hemoglobin (500 mg/dL); Bilirubin: Conjugated and Unconjugated (up to 0.2 mg/mL each); and Rheumatoid Factor (up to 200 IU/mL). However, individual samples occasionally showed > ± 10% interference.

Hook Effect: Not applicable. The IMMULITE® 2000 Anti-CCP assay is a 2-cycle assay with sample containing anti-CCP antibodies first binding to the CCP peptide immobilized on the polystyrene capture bead. Excess unbound antibody is removed by washing prior to the second cycle reagent incubation. During the second cycle, an anti-human IgG alkaline phosphatase conjugate binds in turn to the anti-CCP antibody bound to the bead.

# Traditional 510(k) Premarket Notification IMMULITE ${ \mathfrak { P } } _ { 2 0 0 0 }$ Anti-CCP IgG Assay 510(k) Summary of Safety and Effectiveness

Assay response is positively related to the amount of anti-CCP antibody bound to the capture bead up to the point where the CCP determinants are saturated with antibody, at which point the response plateaus. Any unbound anti-CCP beyond the reportable range of the assay and in excess of saturation is removed by washing prior to contact with the reagent conjugate and there is no risk that a hook effect will be observed.

# f. Assay cut-off:

A high Anti-CCP IgG positive defibrinated plasma unit was arbitrarily assigned with a value of 1000 U/mL. A lot of reference calibrators was prepared by diluting the positive unit with negative normal human serum. The reference calibrators were value-assigned by the dilution factor in relationship to the neat values of $1 0 0 0 \ \mathrm { U / m L }$

A total of 388 samples consisting of 212 apparently healthy samples, 106 RA positive samples, 70 anti-CCP positive samples, as determined by a 3rd party method, were tested with IMMULITE 2000 Anti-CCP Kit and the DIASTAT Anti-CCP ELISA.

The cutoff of the IMMULITE® 2000 Anti-CCP IgG assay was determined with positive and negative patient samples by a ROC analysis, with a balanced consideration of sensitivity and specificity. A result greater than or equal to 4U/mL indicates that anti-CCP IgG antibodies were detected in the sample. A result of less than 4U/mL indicates that anti-CCP IgG antibodies were not detected in the sample.

2. Comparison Studies a. Method Comparison with predicate device:

Method Comparison: The IMMULITE® 2000 Anti-CCP IgG assay was compared to the predicate Axis-Shield DIASTATTM Anti-CCP assay using two lots of reagents. Each sample was tested in singlicate using 3 IMMULITE® 200 instruents. For reagent lot 1, 255 unaltered patient serum samples were tested, 229 of which were determined to be reactive and 26 nonreactive using the DIASTAT'TM assay. For reagent lot 2, 256 unaltered patient serum samples were tested, 230 of which were determined to be reactive and 26 nonreactive using the DIASTATTM assay. Results are shown in the tables below.

# Reagent lot 1:

IMMULITE 2000 Anti-CCP IgG   

<table><tr><td>DIASTAT</td><td>Reactive</td><td>Non-Reactive</td><td>Percent Positive Agreement</td><td>Percent Negative Agreement</td></tr><tr><td>Positive</td><td>1.99</td><td>30</td><td></td><td></td></tr><tr><td>Negative</td><td>14</td><td>12</td><td>86.9%</td><td>46.2%</td></tr></table>

Total Agreement: $8 2 . 2 \%$

# Reagent lot 2:

<table><tr><td colspan="5">IMMULITE 2000 Anti-CCP IgG</td></tr><tr><td>DIASTAT</td><td>Reactive</td><td>Non-Reactive</td><td>Agreement</td><td>Percent Positive Percent Negative Agreement</td></tr><tr><td>Positive</td><td>198</td><td>32</td><td></td><td></td></tr><tr><td>Negative</td><td>15</td><td>11</td><td>86.1%</td><td>42.3%</td></tr></table>

Total Agreement: $8 1 . 6 \%$

# b. Matrix Comparison:

Thirty-nine matched serum and plasma samples were collected in the following anticoagulant tubes: serum clot tube, Lithium Heparin plasma tube, serum separator tube (SST), and EDTA plasma tube. Twenty-one of the 39 samples were spiked to achieve Anti-CCP levels across the assay measuring range. Data was analyzed using Deming regression plots.

<table><tr><td rowspan=1 colspan=1>SERUM vs.</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Means</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.020</td><td rowspan=1 colspan=1>-0.46</td><td rowspan=1 colspan=1>52.9 U/mL</td></tr><tr><td rowspan=1 colspan=1>SST Serum</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.020</td><td rowspan=1 colspan=1>-0.52</td><td rowspan=1 colspan=1>53.0 U/mL</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.010</td><td rowspan=1 colspan=1>-0.31</td><td rowspan=1 colspan=1>52.2 U/mL</td></tr><tr><td rowspan=1 colspan=5>52.2 U/mLSerum: 52.3 U/mL</td></tr></table>

# 3. Clinical Studies:

# aClinical Sensitivity and Specificity

Clinical Performance Study: The assay was performed on the IMMULITE® 2000 to assess the clinical sensitivity and specificity of well-characterized samples.

A total of 1512 patient serum samples were collected for the study. 1048 samples were rheumatoid arthritis (RA) positive and the remaining 464 samples were from non-RA patients with potentially cross-reactive diseases. RA positive patients were classified according to the ACR criteria.

IMMULITE 2000 Anti-CCP IgG   

<table><tr><td>Clinical Status</td><td>Reactive</td><td>Non- Reactive</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>Positive</td><td>667</td><td>.381</td><td></td><td></td></tr><tr><td>Negative</td><td>14</td><td>450</td><td>63.6%</td><td>97.0%</td></tr></table>

b. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical Cut-off: Same as assay cut-off.

5. Expected Values/Reference Range:

A total of 200 serum samples from presumed healthy male and female donors were analyzed using the IMMULITE® 2000 Anti-CCP IgG assay. The results from this study suggest a median of <1.5 U/mL, and a 99th percentile of 4.06 U/mL. Expected values in the normal population should be negative. Each laboratory should establish a reference range appropriate to their patient populations and clinical practice.

# Traditional 510(k) Premarket Notification IMMULITE ${ \mathfrak { P } } _ { 2 0 0 0 }$ Anti-CCP IgG CVM 510(k) Summary of Safety and Effectiveness

# IMMULITE® 2000 Anti-CCP IgG CVM

510(k) Summary as Required by 21 CFR 807.92

A. 510(k) Number B. Purpose for Submission C. Measurand D. Type of test E. Applicant:

New device

Anti-cyclic citrullinated peptide (CCP) antibodies

Calibration verification material for IMMULITE Anti-CCP IgG assay

Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue   
Tarrytown, NY 10591

F. Proprietary and Established Name: G. Regulatory Information:

IMMULITE® 2000 Anti-CCP IgG Calibration Verification Material

1. Regulation section:

21 CFR 862.1660

2. Classification:

Class I (reserved)

3. Products Codes:

JJX  Single Analyte Control (assayed and unassayed

4. Panel:

Clinical Chemistry (75)

H. Intended Use:

The IMMULITE 2000 Anti-CCP IgG Calibration Verification Material is for in vitro diagnostic use, as a control for calibration verification of the IMMULITE® 2000 Anti-CCP IgG assay on the IMMULITE 2000 system.

# I. Device Description:

The IMMULITE Anti-CCP IgG Calibration Verification Material consists of one set of four vials, containing low, intermediate and high levels of lyophilized human serum with IgG reactive to cyclic citrullinated peptide (CCP), in buffer with preservative, plus an anti-CCP-free sample.

Source materials derived from human blood were tested and found nonreactive for syphilis; for antibodies to HIV 1 and 2; for hepatitis B surface antigen; and for antibodies to hepatitis C.

J. Substantial Equivalence Information:

Predicate device name: Elecsys Anti-CCP CalCheck

510(k) number: K091601

# Traditional 510(k) Premarket Notification IMMULITE ${ \mathfrak { P } } _ { 2 0 0 0 }$ Anti-CCP IgG CVM 510(k) Summary of Safety and Effectiveness

# Comparison with predicate:

A comparison of the device features, intended use, and other information demonstrates that the IMMULITE $\textcircled { 1 3 } 2 0 0 0$ Anti-CCP IgG Calibration Verification Material is substantially equivalent to the predicate device, Roche Elecsys Anti-CCP CalCheck, as summarized in the following tables.

<table><tr><td rowspan=1 colspan=3>SIMILARITIES</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>IMMULITE Anti-CCP IgGCVM</td><td rowspan=1 colspan=1>Elecsys Anti-CCP CalCheck</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For in vitro diagnostic use, as acontrol for calibrationverification of Anti-CCP IgGassay.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute with distilled ordeionized water</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>DIFFERENCES</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>IMMULITE Anti-CCP IgGCVM</td><td rowspan=1 colspan=1>Elecsys Anti-CCP CalCheck</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>For use on IMMULITE 2000analyzer</td><td rowspan=1 colspan=1>For use on Elecsys 2010,MODULAR ANALYTICS E170,cobas e411 and cobas e601analyzers</td></tr><tr><td rowspan=1 colspan=1>CVM Levels</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td></tr></table>

# K. Standard/Guidance Documents Referenced:

Guidance for Industry and FDA Staff  Assayed and Unassayed Quality Control Material

# Traditional 510(k) Premarket Notification IMMULITE® 2000 Anti-CCP IgG CVM 510(k) Summary of Safety and Effectiveness

# L. Test Principle:

Not Applicable

# M. Performance Characteristics

6. Analytical Performance:

a. Precision/Reproducibility: Not Applicable b. Linearity/assay reportable range: Not Applicable c. Traceability, Stability, Expected values:

Traceability - Since there is no recognized standard reference material for Anti-CCP, the IMMULITE 2000 Anti-CCP IgG assay is traceable to an internal standard and manufactured using qualified materials and measurement procedures. The IMMULITE Anti-CCP Calibration Verification Material (CVM) is traceable to this standard.

Stability - Open vial stability  Freshly opened and reconstituted IMMULITE 2000 Anti-CCP CVMs showed 30 days open vial stability when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ Unopened stability is indicated by expiration date on the label when stored at $2 . 8 ^ { \circ } \mathrm { C }$ .

Value Assignment: The Anti-CCP reference calibrator values were assigned by using an approved internal standard. This reference standard lot is used to assign Anti-CCP IgG CVMs. Quality control is then performed by calculating the recovery of controls using the reference calibration verification material.

Each CVM level below was run in duplicate on 3 different reagent kit lots (Lot 201, 202 and 211) and 14-15 runs per lot for a total of 86 replicates. Five instruments were used to carry out all the runs. The analyte values were calculated based on the recovered values for each run independently. The average analyte recovered for each CVM level determined the value assigned to the Target Mean.

The Guideline Range ( $9 5 \%$ confidence interval) for each CVM level was established based on the Target Mean and $\pm 2$ Standard Deviations (SD).

<table><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Catalog andLot number</td><td rowspan=1 colspan=1>Target Mean(U/mL)*</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=2>GuidelineRange(U/mL)</td><td rowspan=1 colspan=1>TotalCV%</td><td rowspan=1 colspan=1>SpecCV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>L2PICVM1 Dxxx</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>≤1.50</td><td rowspan=1 colspan=1>NA**</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>L2PICVM2Dxxx</td><td rowspan=1 colspan=1>6.19</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>5.37</td><td rowspan=1 colspan=1>7.00</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>10%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>L2PICVM3 Dxxx</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>8.85</td><td rowspan=1 colspan=1>85.3</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>10%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>L2PICVM4 Dxxx</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>21.09</td><td rowspan=1 colspan=1>167</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>10%</td></tr></table>

\* note that CVM value assignment is lot-specific $\# * \mathbb { N } \mathbf { A } = \mathbb { N } \mathbf { o t }$ Applicable

d. Detection limit: Not Applicable e. Analytical Specificity: Not Applicable f. Assay cut-off: Not Applicable

7. Comparison Studies

a. Method Comparison with predicate device: Not Applicable b. Matrix Comparison: Not Applicable

8. Clinical Studies:

a. Clinical Sensitivity and Specificity: Not Applicable Other clinical supportive data (when a. and b. are not applicable): Not Applicble

Clinical Cut-off: Not Applicable

10. Expected Values/Reference Range: See Value Assignment above.

Siemens Healthcare Diagnostics c/o Susan Brocchi Sr. Regulatory Affairs Specialist 511 Benedict Avenue Tarrytown, NY 10591

Re: k121576 Trade/Device Name: IMMULITE 2000 Anti-CCP IgG Assay and IMMULITE 2000 AntiCCP IgG Calibration Verification Material Regulation Number: 21 $\ S$ CFR 866.5775 Regulation Name: Rheumatoid factor immunological test system Regulatory Class: Class II Product Code: NHX, JIT Dated: March 29, 2013 Received: April 1, 2013

Dear Ms. Brocchi:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class ⅡI (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be fod in he ode  Federal Regulations, Tit, Parts 800 to Indition, FA y publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/default.htm.

Sincerely yours,

# Maria M. Chan -S

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health (OIR)   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k121576

Device Name: IMMULITE $^ \mathrm { \textregistered }$ 2000 Anti-CCP IgG Assay and Calibration Verification Material

Indications for Use: The IMMULITE 2000 Anti-CCP IgG assay is an in vitro diagnostic immunoassay for the semi-quantitative determination of the IgG class of autoantibodies specific to cyclic citrullinated peptide (CCP) in human serum (including Serum Separator Tubes) or plasma (EDTA or lithium heparin) on the IMMULITE 2000 system. Detection of anti-CCP antibodies is used as an aid in the diagnosis of Rheumatoid Arthritis (RA) and should be used in conjunction with other clinical information. Autoantibody levels represent one parameter in a multi-criteria diagnostic process, encompassing both clinical and laboratory-based assessments.

The IMMULITE 2000 Anti-CCP IgG Calibration Verification Material (CVM) is for in vitro diagnostic use, as a control for calibration verification of the IMMULITE 2000 Anti-CCP IgG assay on the IMMULITE 2000 system.